- Home
- IMA vs XBIT Comparison
IMA vs XBIT Comparison
Compare IMA & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMA | XBIT |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 73.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | IMA | XBIT |
|---|---|---|
| Price | $6.70 | $2.53 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 48.2K | 46.4K |
| Earning Date | 02-15-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.70 | $2.09 |
| 52 Week High | $18.00 | $4.00 |
Technical Indicators
Market Signals| Indicator | IMA | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.23 |
| Support Level | N/A | $2.49 |
| Resistance Level | N/A | $2.64 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 63.16 |
Price Performance
Historical ComparisonAbout IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.